Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of conditioning agents and stem cell engineering to allow expanded use of stem cell transplantation and ex vivo gene therapy, a technique in which genetic manipulation of cells is performed outside the body prior to transplantation. The company's lead product candidate is JSP191, which is in clinical development as a conditioning antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is based in Redwood City, California.

Jasper Therapeutics, Inc.

Jasper Therapeutics is a biotechnology company on a mission to make safer and potentially curative therapy possible for more patients in need. We are bringing together a team of biotech veterans, leading academic institutions and a strong syndicate of healthcare-focused investors to achieve our vision of developing new therapies for diseases of mast and stem cells, and safer and more effective conditioning for monogenetic diseases.

Abingworth

Alexandria Venture Investments

Amgen

Apeiron Investment Group

Avego Healthcare Capital

Roche Venture Fund

Kingdon Capital

Woodline Partners

Federated Kaufmann Fund

Velan Capital

Qiming Venture Partners USA

Citadel

TSVC

Surveyor Capital

Jasper Therapeutics

Today, Jasper provided a recap its recent accomplishments, including the authorization by the European Medicines Agency of the Company’s Clinical Trial Applications for its Phase 1b/2a BEACON study of briquilimab in CSU and Phase 1b/2a SPOTLIGHT study in CIndU. Read the full announcement here: https://lnkd.in/gcDX6niJ

Results from two studies evaluating briquilimab as a conditioning agent for stem cell transplant were presented at the American Society of Hematology 2023 annual meeting. Read a summary of the results presented here: https://lnkd.in/gJ4GFQGU

Fascinating paper which concluded: A large proportion of CSU patients treated with H1AH-based therapies had uncontrolled disease, contributing to increased HRU and patient burden. Non-responders had more comorbidities and HRU at baseline and follow-up, with steep increases in follow-up hospitalizations relative to baseline, highlighting an urgent need for early disease control.  
At Jasper we are seeking to address this high unmet need. #Jaspertherapeutics

Jasper is pleased to announce that the first patient has been dosed in the Phase 1b/2a BEACON study evaluating briquilimab in CSU

Read the full announcement here: https://lnkd.in/gX4DNe7h

The Jasper team wishes everyone a restful and joyful Thanksgiving holiday!

Jasper is excited to participate in the American College of Allergy, Asthma and Immunology (ACAAI) 2023 Annual Meeting. Tomorrow at 3:45pm PT Charles C. will be presenting preclinical data demonstrating that briquilimab prevents passive systemic anaphylaxis in mice expressing chimeric human/mouse CD117 during the “Meet the Authors” poster session in Exhibition Hall C (Level 1). View the poster here: https://lnkd.in/gc9aQ5Es

CSU affects 40 million people worldwide, and around 60% need an option beyond standard-of-care antihistamines, according to Novartis.  As a clinician, it is exciting to see potential new medicines coming into clinic for patients with high unaddressed needs.

https://lnkd.in/g9-qEBKj

Jasper is pleased to report third quarter 2023 financial results. Read the full announcement here: https://lnkd.in/greDRAD4

Jasper Therapeutics Announces Oral Presentation of Positive Final Results from Phase 1 Study of Briquilimab in Patients with AML or MDS Undergoing Hematopoietic Cell Transplant at ASH 2023.

Read the full announcement here: https://lnkd.in/dsf4EK7S

	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
revenue
cost of revenue		21K -	566K 2,595.24%	1.31M 131.45%	1.11M 15.42%
gross profit		-21K -	-566K 2,595.24%	-1.31M 131.45%	-1.11M 15.42%
selling and marketing expenses					-1.11M -
general and administrative expenses	1.09K -	4.80M 439,460.44%	11.41M 137.75%	16.57M 45.19%	17.08M 3.06%
selling general and administrative expenses	1.09K -	4.80M 439,460.44%	11.41M 137.75%	16.57M 45.19%	15.97M 3.63%
research and development expenses	3.62K -	15.88M 438,899.45%	25.42M 60.05%	34.63M 36.21%	53.41M 54.25%
other expenses		-111K -	-80K 27.93%	586K 832.50%
cost and expenses	4.45K -	20.68M 464,269.11%	36.83M 78.08%	51.20M 38.99%	70.49M 37.68%
operating expenses	4.45K -	20.68M 464,269.11%	36.83M 78.08%	51.20M 38.99%	69.38M 35.52%
interest expense				-13.51M -
ebitda	-277 -	-9.81M 3,540,694.22%	-43.11M 339.53%	-64.12M 48.74%	-69.38M 8.20%
operating income	-4.71K -	-20.68M 439,029.51%	-36.83M 78.08%	-51.20M 38.99%	-70.49M 37.68%
depreciation and amortization	4.71K -	10.88M 230,791.72%	-6.28M 157.71%	-12.93M 105.94%	1.11M 108.57%
total other income expenses net	-277 -	-10.99M 3,965,964.98%	6.20M 156.40%	13.51M 118.06%	4.40M 67.46%
income before tax	-4.99K -	-31.67M 634,931.08%	-30.64M 3.26%	-37.69M 23.00%	-66.09M 75.38%
income tax expense	-277 -	-38.45K 13,781.23%	-6.65M 17,202.54%	-13.51M 103.08%	-1.63M 87.95%
net income	-4.99K -	-31.67M 634,931.08%	-23.98M 24.27%	-24.17M 0.79%	-64.47M 166.67%
weighted average shs out		277.07K -	1.14M 311.22%	3.65M 220.20%	10.44M 186.14%
weighted average shs out dil		277.07K -	1.14M 311.22%	3.65M 220.20%	10.44M 186.14%
eps		-114.30 -	-21.05 81.58%	-6.63 68.50%	-6.18 6.79%
epsdiluted		-114.30 -	-21.05 81.58%	-6.63 68.50%	-6.18 6.79%

NASDAQ:JSPR

Jasper Therapeutics

Last Close

21.26

26/07 20:00

Market Cap

299.75M

Beta: 1.99

Volume Today

193.96K

Avg: 1.11M

PE Ratio

−22.01

PFCF: −2.88

Preview